- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05104983
Stoppa TSC-debut och progression 2B: Sirolimus TSC Epilepsi Prevention Study (TSC-STEPS)
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.
This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of TSC, including epilepsy. This will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a rational, mechanism-based therapeutic approach.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Förenta staterna, 90095
- University of California at Los Angeles
-
Palo Alto, California, Förenta staterna, 94304
- Stanford University
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Boston Children's Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27510
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- University of Texas HSC at Houston
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Seattle Children's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation). Corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).
- Has a confirmed diagnosis of TSC based on established clinical or genetic criteria
Exclusion Criteria:
- Prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline EEG.
- Has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure.
- Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.
- Has a significant illness or active infection at the time of the baseline screening visit
- Has a history of significant prematurity, defined as gestational age <30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than TSC would convey additional risk of seizures or neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures).
- Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject.
- Prior, planned or anticipated neurosurgery within 3 months of the baseline visit
- Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).
- Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
Placebo |
Matching placebo |
|
Experimentell: Sirolimus
Sirolimus |
The investigational drug product to be used in this study is sirolimus, provided in oral suspension. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Efficacy -- time to seizure onset
Tidsram: 12 months of age
|
Time to seizure onset, comparing sirolimus with placebo |
12 months of age
|
|
Safety -- adverse events
Tidsram: 12 months of age
|
Percentage of subjects reporting severe (CTCAE v5.0 grade >= 3) adverse event (AE) or serious adverse event (SAE), comparing sirolimus with placebo. |
12 months of age
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Neurodevelopmental Outcomes
Tidsram: 12 and 24 months of age
|
Neurodevelopmental outcomes at the end of treatment, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
Quality of Life Outcomes
Tidsram: 12 and 24 months of age
|
Patient and caregiver quality of life, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
EEG Biomarkers
Tidsram: 12 and 24 months of age
|
EEG measures of neuronal connectivity, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
MRI Biomarkers
Tidsram: 12 and 24 months of age
|
MRI measures of neuronal connectivity, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
Sirolimus Precision Dosing
Tidsram: 12 months of age
|
Validate the feasibility and effectiveness of sirolimus precision dosing in infants with TSC |
12 months of age
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Darcy A Krueger, MD, PhD, Children's Hospital Medical Center, Cincinnati
- Huvudutredare: Martina Bebin, MD, MPA, University of Alabama at Birmingham
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Neoplasmer
- Genetiska sjukdomar, medfödda
- Neurodegenerativa sjukdomar
- Medfödda abnormiteter
- Heredodegenerativa störningar, nervsystemet
- Neoplastiska syndrom, ärftligt
- Neurokutana syndrom
- Hamartoma
- Neoplasmer, multipla primära
- Missbildningar av kortikal utveckling, grupp I
- Missbildningar av kortikal utveckling
- Missbildningar i nervsystemet
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Tuberös skleros
- Epilepsi
- Organiska kemikalier
- Makrolider
- Laktoner
- Sirolimus
Andra studie-ID-nummer
- 2021-0438
- 1R01FD007275 (U.S.A. FDA-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .